{"id":"safetynadol","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":{"setId":"b956d527-7ea7-e084-e053-2a95a90a866d","title":"SAFETYNADOL (ACETAMINOPHEN) TABLET, COATED [SINEW PHARMA INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SafeTynadol® appears to be a branded acetaminophen product marketed with safety enhancements, likely involving modified-release technology or formulation adjustments to minimize peak plasma concentrations and reduce the risk of liver injury. The product name suggests a focus on safer dosing or metabolism compared to standard acetaminophen formulations.","oneSentence":"SafeTynadol® is a modified formulation of acetaminophen designed to reduce hepatotoxicity risk through enhanced safety mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:50:08.531Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pain relief and fever reduction (marketed indication presumed)"}]},"trialDetails":[{"nctId":"NCT05563961","phase":"NA","title":"A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers","status":"UNKNOWN","sponsor":"Sinew Pharma Inc.","startDate":"2022-10-28","conditions":"Hepatitis, Pharmacology","enrollment":48},{"nctId":"NCT03451487","phase":"NA","title":"A Randomized, Single-blind, Parallel Group and Multiple - Dose Design Study","status":"COMPLETED","sponsor":"Sinew Pharma Inc.","startDate":"2022-05-19","conditions":"Acetaminophen Toxicity","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SNP-810","Placebo B + Tween20 and PEG400"],"phase":"marketed","status":"active","brandName":"SafeTynadol®","genericName":"SafeTynadol®","companyName":"Sinew Pharma Inc.","companyId":"sinew-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SafeTynadol® is a modified formulation of acetaminophen designed to reduce hepatotoxicity risk through enhanced safety mechanisms. Used for Pain relief and fever reduction (marketed indication presumed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}